PMID- 19593660
OWN - NLM
STAT- MEDLINE
DCOM- 20100325
LR  - 20220330
IS  - 1573-7373 (Electronic)
IS  - 0167-594X (Linking)
VI  - 96
IP  - 2
DP  - 2010 Jan
TI  - Salvage therapy with single agent bevacizumab for recurrent glioblastoma.
PG  - 259-69
LID - 10.1007/s11060-009-9957-6 [doi]
AB  - A retrospective evaluation of single agent bevacizumab in adults with recurrent 
      glioblastoma (GBM) with an objective of determining progression free survival 
      (PFS). There is no standard therapy for recurrent GBM after failure of 
      alkylator-based chemotherapy. A total of 50 adults, ages 36-70 years (median 64), 
      with recurrent GBM were treated. All patients had previously been treated with 
      surgery, concurrent radiotherapy and temozolomide, post-radiotherapy temozolomide 
      and in 34 patients, one salvage regimen (PCV: 21, cyclophosphamide: 13). A total 
      of 13 patients underwent repeat surgery. Patients were treated at first or second 
      recurrence with bevacizumab, once every 2 weeks, defined as a single cycle. 
      Neurological evaluation was performed every 2 weeks and neuroradiographic 
      assessment following the initial 2 cycles of bevacizumab and subsequently after 
      every 4 cycles of bevacizumab. A total of 468 cycles of bevacizumab (median 2 
      cycles; range 1-30) was administered. Bevacizumab-related toxicity included 
      fatigue (16 patients; 4 grade 3), leukopenia (9; 1 grade 3), anemia (5; 0 grade 
      3), hypertension (7; 1 grade 3), deep vein thrombosis (4; 1 grade 3) and wound 
      dehiscence (2; 1 grade 3). 21 patients (42%) demonstrated a partial radiographic 
      response and 29 (58%) progressive disease following 1-2 cycles of bevacizumab. 
      Time to tumor progression ranged from 0.5 to 15 months (median: 1.0 months). 
      Survival ranged from 2 to 17 months (median: 8.5 months). 6-month and 12-month 
      PFS were 42% and 22% respectively. Single agent bevacizumab demonstrated efficacy 
      and acceptable toxicity in this cohort of adults with recurrent 
      alkylator-refractory GBM.
FAU - Chamberlain, Marc C
AU  - Chamberlain MC
AD  - Department of Neurology and Neurosurgery, University of Washington, Fred 
      Hutchinson Cancer Research Center, Seattle, WA 98109-1023, USA. 
      chambemc@u.washington.edu
FAU - Johnston, Sandra K
AU  - Johnston SK
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20090711
PL  - United States
TA  - J Neurooncol
JT  - Journal of neuro-oncology
JID - 8309335
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - AYI8EX34EU (Creatinine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Bevacizumab
MH  - Blood Cell Count
MH  - Brain Neoplasms/*drug therapy/mortality
MH  - Creatinine/urine
MH  - Disease-Free Survival
MH  - Female
MH  - Glioblastoma/*drug therapy/mortality
MH  - Humans
MH  - Injections, Intravenous/methods
MH  - Magnetic Resonance Imaging/methods
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*drug therapy/mortality
MH  - Retrospective Studies
MH  - Salvage Therapy/*methods
MH  - Treatment Outcome
EDAT- 2009/07/14 09:00
MHDA- 2010/03/26 06:00
CRDT- 2009/07/14 09:00
PHST- 2009/04/07 00:00 [received]
PHST- 2009/06/22 00:00 [accepted]
PHST- 2009/07/14 09:00 [entrez]
PHST- 2009/07/14 09:00 [pubmed]
PHST- 2010/03/26 06:00 [medline]
AID - 10.1007/s11060-009-9957-6 [doi]
PST - ppublish
SO  - J Neurooncol. 2010 Jan;96(2):259-69. doi: 10.1007/s11060-009-9957-6. Epub 2009 
      Jul 11.